Neoplastic Process

Bristol Myers Squibb Completes $4.8 Billion Acquisition of Mirati Therapeutics

2 days ago talkbio0Tagged Acquisition, KRAS NP_004976.2:p.G12C, Myers Squibb, Neoplasms

Bristol Myers Squibb; Mirati Therapeutics; acquisition; $4.8 billion; KRAZATI; oncology; KRAS G12C

FDA Lifts Partial Hold on Merck and Daiichi Sankyo’s B7-H3 ADC Trial for Lung Cancer[6]

3 days ago talkbio0Tagged CD276 gene, Daiichi, Deruxtecan, I-DXd, IDeate-Lung02, ifinatamab, Lifting, Merck, Sankyo, Small cell carcinoma of lung, therapeutic autologous dendritic cells, United States Food and Drug Administration

FDA; partial hold lifted; Merck; Daiichi Sankyo; ifinatamab deruxtecan; I-DXd; B7-H3 ADC; small cell lung cancer; IDeate-Lung02

Eisai Licenses Nuvation Bio’s Taletrectinib for ROS1+ Lung Cancer in Europe and Asia

3 days ago talkbio0Tagged Eisai, licensing agreement, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Nuvation Bio, ROS1 gene, taletrectinib

Eisai; Nuvation Bio; taletrectinib; ROS1+ NSCLC; licensing agreement; lung cancer

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

3 days ago talkbio0Tagged annamycin, Clinical Trials, Leukemia, Myelocytic, Acute, milestones, MIRACLE trial, Moleculin, WP1066

Moleculin; MIRACLE trial; Annamycin; WP1066; AML; clinical trials; 2026 milestones

Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting Durable Complete Response and 66.7% ORR in Advanced GC/GEJ

3 days ago talkbio0Tagged ASCO GI 2026, CAR-T, Claudin-18 Isoform A2, IMC002, Immunofoco, In complete remission, Malignant neoplasm of stomach, ORR

Immunofoco; IMC002; ASCO GI 2026; CAR-T; CLDN18.2; gastric cancer; complete response; ORR

AbbVie Pays $650M Upfront to RemeGen for PD-1/VEGF Bispecific RC148 Rights Outside China

4 days ago talkbio0Tagged AbbVie, Antibodies, Bispecific, Neoplasms, PD-1/VEGF, RC148, RemeGen

AbbVie; RemeGen; RC148; PD-1/VEGF; bispecific antibody; oncology; licensing deal; $650M; $5.6B

Aktis Oncology’s 25% IPO jump lifts optimism for a biotech IPO rebound in 2026

7 days ago talkbio0Tagged Aktis, AKTS, Biotech IPOs, bounce, Capital Markets, CD276 gene, Eli Lilly backing, IPO, NECTIN4 gene, Neoplasms, Radiopharmaceuticals, Window (physical object)

Aktis Oncology IPO; AKTS; 2026 biotech IPOs; IPO bounce; radiopharmaceuticals; Eli Lilly backing; biotech capital markets; Nectin-4; B7-H3; IPO window 2026

Speculation builds about a multibillion-dollar takeout of Revolution Medicines

7 days ago talkbio0Tagged AbbVie, Acquisition, daraxonrasib, financial, J.P. Morgan Healthcare Conference, Merck, Neoplasms, RAS-driven cancers, Revolution Medicines, rumors, RVMD, takeover talks, Wall Street Journal

Revolution Medicines; RVMD; Merck; AbbVie; takeover talks; acquisition rumors; buyout speculation; Financial Times report; Wall Street Journal; J.P. Morgan Healthcare Conference; multibillion-dollar deal; oncology; RAS-driven cancers; daraxonrasib

Roche returns to Chinese biotech MediLink for another ADC pact

7 days ago talkbio0Tagged Antibody-Drug Conjugates, CD276 gene, China, Neoplasms, Platform, Roche (company), Small cell carcinoma of lung, small-cell lung cancer, Solid Neoplasm, therapeutic autologous dendritic cells, TMALIN, YL201

Roche; MediLink Therapeutics; YL201; antibody-drug conjugate; ADC; B7-H3; TMALIN platform; small-cell lung cancer; SCLC; solid tumors; licensing deal; oncology; China biotech

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

7 days ago talkbio0Tagged Autoimmune, cardiometabolic, Eli, Eli Lilly, Immunotherapy for cancer, InduPro * *, Inflammatory disorder, M&A, Neoplasms, Neuroinflammation, NLRP3 inhibitors, Obesity, Ventyx Biosciences, VTX3232, VTX958

Eli Lilly; Lilly; Ventyx Biosciences; InduPro; inflammatory diseases; oncology; NLRP3 inhibitors; tamuzimod; VTX2735; VTX3232; VTX958; autoimmune; obesity; cardiometabolic; neuroinflammation; M&A; biotech deal; cancer immunotherapy